Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis

    NEXT STORY
    The 2019 U.S. HIV Market: Analyses & Forecasts Through 2014-2024
    PREV STORY
    AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Sanofi : FDA accorde un examen prioritaire au cemiplimab dans le traitement potentiel du carcinome épidermoïde cutané au stade avancé

    author_avatar
    NASDAQ Market News

    Axiom Real-Time Metrics Showcasing Fusion eClinical Suite at the ASCO Annual Meeting 2018 in Chicago

    TORONTO, June 01, 2018 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics, premier provider of unified ...

    author_avatar
    NASDAQ Market News

    Inivata Achieves Major Milestone with Draft Medicare Local Coverage Determination (LCD) for InVisionFirst™-Lung Liquid Biopsy Test

    Inivata Achieves Major Milestone with Draft Medicare Local Coverage Determination (LCD) for InVisionFirst™-Lung Liquid ...

    author_avatar
    NASDAQ Market News